Title of Invention

"COMPOSITION FOR ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE"

Abstract

The present invention relates to a composition for oral administration of tamsulosin hydrochloride comprising tamsulosin hydrochloride, polyvinylacetate, and a water-soluble hydroxypropylmethylcellulose, wherein the amount of polyvinylacetate ranges from 20 to 1000 parts by weight based on 1 part by weight of tamsulosin hydrochloride and wherein the amount of water-soluble hydroxypropylmethylcellulose ranges from 0.1 to 500 parts by weight based on 1 part by weight of tamsulosin hydrochloride.

Full Text

COMPOSITION FOR ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLOREDE AND CONTROLLED RELEASE GRANULE FORMULATION COMPRISING SAME Field of the Invention The present invention relates to a composition for oral administration of tamsulosin hydTocbJoride, which exhibits an excellent stability and a sustained release of tamsulosin hydrochioride, and a controlled release granule formulation comprising the same. Description of the Prior Art Tamsulosin hydrochioride are currently available for treating benign prostatic hypertrophy, and there have been made many attempts to develop a controlled release formulation of tamsulosin hydrochioride having^ood stability and an extended release rate. For example, European Patent Publication No. 80341A discloses an oral formulation for controlled release of tamsulosin which contains multiple drug preparations; and Korean Patent Publication No. 1993-7245 discloses a controlled release formulation for oral use comprising the drug, an aggregate-forming agent such as cellulose, chitin and chitosan, and an insoluble polymer. However the stability and the release characteristics of these formulations fluctuate unsatisfactorily depending on the retained food or pH changes in the gastroenteric organs. The present inventors have endeavored to develop a composition having good stability and sustained release characteristics of tamsulosin hydrochioride under any digestive conditions; and have unexpectedly found that a composition comprising tamsulosin hydrochioride, polyvinyl acetate and a water-soluble hydroxypropylmethylcellulose is particularly suitable for oral administration. Summary of the Invention Accordingly, it is a primary object of the present invention to provide a novel tamsulosin hydrochloride composition which exhibits high stability and satisfactory sustained release characteristics of tamsulosin hydrochloride upon oral administration. It is another object of the present invention to provide a controlled release granule formulation comprising said composition. In accordance with one aspect of the present invention, there is provided a composition for oral administration of tamsulosin hydrochloride comprising tamsolosin hydrochloride, polyvinylacetate, and a water-soluble hydToxypropylTnethylcellulose. In accordance with another aspect of the present invention, there is provided a sustained release granule of tamsulosin hydrochloride comprising tamsulosin hydrochloride, polyvinylacetate, a water-soluble nydroxvpropylmethyfcellulose, and a granulating agent. Brief Description of the Drawings The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings, which respectively show: : FIG. 1: Dissolution profiles of tamsulosin hydrochloride observed for the hard capsule prepared in Example 17 and Hamal capsule (Jeil Pharm., Korea); FIGs. 2A and 2B: Dissolution profiles of tamsulosin hydrochloride observed for the hard capsule prepared in Example 17 (A) and Harmal capsule (B) after storage for 10 days under the condition of Test Example 2; and FIGs. 3A and 3B: Microscopic photographs of the coated granule prepared in Example 15 (A) and the granule of Harnal capsule (B). Detailed Description of the Invention The composition of the present invention comprises tamsulosin hydrochloride, polyvinylacetate, and a water-soluble hydroxypropylcellulose. The inventive composition may further comprise various granulating agents, coating materials, and pharmaceutically acceptable additives. Each ingredient of the inventive composition and granule formulation is described in detail as follows. Tamsulosia hvdrocMoride Tamsulosin hydrochloride, the active ingredient of the inventive cornposrtron. has a low water-solubility. A typical daily do of tamsulosin hydrochloride in case of treating urination disorder accompanying benign prostatic hypertrophy ranges from 0.2 to 0.8 mg, and it should be administered once a day 30 min before a meal. However, i: should be understood mat the dosage of tamsulosin hydrochloride should be determined in light of various relevant factors including the condition to be treated, the severity of the patient's symptoms, the route of administration, or the physiological form of the anrkancer agent; and therefore, the dosage suggested above should 4iot be construed to limit the scope of the invention in anyway. Polwinylacetate Polyvinylacetate plays an important role in assisting granulating agent in the process of forming granules and maintaining pores formed in the granules for some period of time after the inventive granule formulation is dissolved in an aqueous medium. Consequently, polyvinylacetate confers on the composition of the inventive composition with sustained release capability of the active ingredient for an extended period of time regardless of pH of the aqueous medium. In the inventive composition, polyvinylacetate may be used alone or in the form of a mixture with other pharmaceutically acceptable materials, preferably in the form of a powder or a suspension containing more than 30% by weight or more of polyvinylacetate. For example, Kollidon SR® (BASF), a powder prepared by mixing polyvinylacetate and polyvinylpyrrolidone at a ratio of 8:2 (w/w) and spray-drying the mixture, and Kollicoat SR30D® (solid content: 30%, BASF), a suspension (or a diluted aqueous solution) prepared by mixing polyvinylacetate, polyvinylpyrrolidone and sodium lauryl sulfate, and suspending the mixture in water, may be used in the present invention as a source of polyvinylacetate. In addition, any pharmaceutically acceptable material may be used as a source of polyvinylacetate insofar as it contains 30% by weight or more of polyvmylacetate. Polyvinylacetate may be employed hi the inventive composition in an amount ranging from 20 to 1000 parts by weight, preferably 40 to 600 parts by weight more preferably 50 to 300 parts by weight based on 1 part by weight of tamsulosin hydrochloride. Water-soluble hydroxypropylmethvlcellulose A water=soiuble hydroxypropylmethylcelkilose (HPMC) controls the initial-phase release of the active ingredient by forming pores, through which the active ingredient is released. In order to obtain a desired sustained release pattern, it is preferable to employ a water-soluble HPMC having a high viscosity, and the desired effect may not be achieved when a low-viscosity water-soluble HPMC is employed. Therefore, the water-soluble HPMC having a high viscosity of more than 10,000 cps, preferably 15,000 to 100,000 cps, is used in the present invention, and representative examples thereof include METOLOSE 60SH, 65SH and 90SH (Shin-Etsu). The water-soluble HPMC may be used in an amount ranging from 0.1 to 500 parts by weight, preferably 1 to 100 parts by weight, more preferably 2 to 50 parts by weight based on 1 part by weight of tamsulosin hydrochloride. A controlled release granule formulation prepared by using the inventive composition may further comprise the following ingredients. Granulating agent The inventive granule formulation may comprise a granulating agent and examples thereof include microcrystalline cellulose, lactose and inorganic carrier such as dibasic calcium phosphate, dibasic calcium phosphate dihydrate and tribasic calcium phosphate, wherein microcrystalline cellulose and dibasic calcium phosphate (e.g. A-Tab®, Rhodia) are prefered. The granulating agent may be used in an amount ranging from 1 to 2000 parts by weight, preferably 10 to 1000 parts by weight based on 1 part by weight of tamsuiosin hydrochloride. Coating material The inventive granule formulation of tamsuiosin hydrochloride may further be coated with a conventional enteric coating material or a polymeric coating material for the purpose of precisely controlling the absorption of the active ingredient in the gastrointestinal treat. Examples of the enteric coating material include hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinylacetate phthalate, cellulose acetate phthalate, shellac, methacrylate-methylmethacrylate copolymer and metfiacrylate-ethylacrylate copolymer. Examples of the polymeric coating material include hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, polyvinylacetate and a mixture thereof. The coating material may be employed in an amount ranging from 0.2 to 100 parts by weight, preferably 1 to 50 parts by weight based on the amount 1 part by weight of tamsuiosin hydrochloride. Pharmaceutically acceptable additives The inventive granule formulation may further comprise conventional pharmaceutically acceptable additives for preparing it into various formulations, and exemplary pharmaceutically acceptable additive include a conventional plasticizer, lubricant and other aid. The pharmaceutical acceptable additive may be employed in an amount ranging from 0.1 to 500 parts by weight, preferably 1 to 200 parts by weight, more preferably 2 to 50 parts by weight based on 1 part by weight of tamsulosin hydrochloride. The inventive cojjapasition of tamsulosin fajdEoehloride may be formulated into a graauk formulation by a conventional method onrnprismg me steps of (i) raixiag the composition with a granulating agent, and (ii) subjecting the mixture to wet grinding, compression molding and spheronizing to obtain a wet granule. The granule may be further coated with a coating material dissolved in water to obtain a coated granule. If necessary, the granule may be further mixed with pharmaceutical acceptable additives and filled into a hard gelatin capsule to obtain a capsule formulation. The following Examples are intended to further illustrate the present invention without limiting its scope. I. Preparation of controlled release granule formulation of tamsulosin hydrochloride Example 1 0.2 part by weight of tamsulosin hydrochloride, 21.0 parts by weight of Kollicoat SR30D (BASF, polyvinylacetate), 5.5 parts by weight of METOLOSE 90SH (water-soluble HPMC; viscosity: 100,000 cps), and 123.5 parts by weight of micro crystalline cellulose (granulating agent) were placed in a high speed mixer, and an appropriate amount of water was added thereto. The mixture was mixed for 10 to 15 min and treated with a wet grinder obtain a ground material, which was passed through a compression mold equipped with a 0.8 mm mesh, and granulated with a sheronizer to obtain a desired granule. Example 2 The procedure of Example 1 was repeated except for using 133.5 parts by weight of dibasic calcium phosphate as a granulating agent, to obtain a desired granule. Example 3 The procedure of Example 1 was repeated except for using 95.5 parts by weight of dibasic ralrrprrt pfafvyhatp dihyrirafp. as a, gTffFWfoting agent, tO obtain a ifegireH gn^mjlp Example 4 The procedure of Example 1 was repeated except for using 128.5 parts by weight of lactose as a granulating agent, to obtain a desired granule. Examples The procedure of Example 1 was repeated except for using a mixture of 60 parts by weight of lactose and 68.5 parts by weight of microcrystalline cellulose as a granulating agent, to obtain a desired granule. Example 6 The procedure of Example 1 was repeated except for using 3.8 parts by weight of METOLOSE 65SH (viscosity: 4,000 cps) instead of METOLOSE 90SH, to obtain a desired granule. Example 7 The procedure of Example 1 was repeated except for using 4.5 parts by weight of METOLOSE 65SH instead of METOLOSE 90SH, to obtain a desired granule. Example 8 The procedure of Example 1 was repeated except for using 70.0 parts by weight of Kollidon SR instead of Kollicoat SR30D, and 34.5 parts by weight of METOLOSE 65 SH instead of METOLOSE 90SH, to obtain a desired granule. Example 9 The procedure of Example 1 was repeated except for using 78.0 parts by weight of Kollidon SR instead of Kollicoat SR30D, and 55.5 parts by weight of microcrystalline cellulose instead of 1233 parts by weight, obtain a desired granule. II. Preparation of coated-controlled release granule of tamsulosin hydrochloride Example 10 150.0 parts by weight of the controlled release granule of tamsulosin hydrochloride obtained in Example 1 was placed in NQ-160 fluidized bed (DALTON) and bottom-sprayed with a coating solution comprising 9.7 parts by weight of Kollicoat SR30D (solid content: 2.9 parts by weight, a coating material), a mixture of 0.56 part by weight of polyvinylpyrrolidone and 0.43 part by weight of propyleneglycol (a plasticizer), and 18.0 parts by weight of distilled water, to obtain a desired coated granule. During the coating, the entrance temperature was 36 to 39°C, exit temperature was 26 to 28°C, the rate of injection of the coating solution was 0.7 to 0.8 ml /min, and the spraying air pressure was 45 to 55 psi. Example 11 The procedure of Example 10 was repeated except for using 3.4 parts by weight of ethylcellulose (IPI) and 7.6 parts by weight of hydroxypropylmethylcellulose (Shrn-Etsu) as a coating material, to obtain a desired coated granule. Example 12 The procedure of Example 10 was repeated except for using a coating solution comprising 12.0 parts by weight of Fndragit L30D-55 (methacrylate-ethylacrylate copolymer, solid content: 3.6 parts by weight, Roehm) as a coating material, 0.54 part by weight of triacetine as a plasticizer and 21.8 parts by weight of water in place of the coating solution of Example 10, to obtain a desired coated granule. Example 13 The procedure of Example 10 was repeated except for using 4.0 parts by weight of hydroxypropylmethylcellulose phthalate (solid content: 3.6 parts by weight, Roehm) as a coating material, to obtain a desired coated granule. Example 14 The procedure of Example 10 was repeated except for using 9.0 parts by weight of Eudragit E-100 (methacrylate-methyhnethacrylate copolymer, solid content 3.6 parts by weight, Roehm) as a coating material, to obtain a desired coated granule. Example 15 The procedure of Example 10 was repeated except for using 153.9 parts by weight of the coated-granule obrained in Example 10 instead of the granule obtained in Example 1, and a coating solution comprising 12.0 parts by weight of Eudragit L30D-55 (methacrylate-ethylacrylate copolymer, solid content: 3.6 parts by weight, Roehm) as a coating material, 0.54 part by weight of triacetine as a plasticizer and 21.8 parts by weight of water in place of the coating solution of Example 10, to obtain a desired coated granule. III. Preparation of hard capsule comprising controlled release granule of tamsulosine hydrochloride Example 16 158.14 parts by weight of the coated granule obtained in Example 13, 0.5 part by weight of talc, and 0.5 part by weight of calcium stearate were mixed, and a hard capsule was filled with the mixture to obtain a desired hard capsule. Example 17 158.14 parts by weight of the coated granule obtained in Example 15, 0.5 part by weight of talc, and 0.5 part by weight of calcium stearate were mixed, and a hard capsule was filled with the mixture to obtain a desired hard capsule. Test Example 1: Dissolution Test A dissolution test for tamsulostn hydrochloride was conducted using the capsule obtained in Example 17 and Harnal (Jeil Pharm.) capsule as a comparative preparation as follows. 500 ml of artificial gastric juice (pH 1.2) containing 1 ml of Tween 80 was used as test solution (1). Each treat capsule was added to test solution (1), the mixture was agitated at 37±0.5°C and 100 rpm for 2 hours, and a 10 ml sample was taken from the test solution (1). Then, the test solution (1) was changed with test solution (2), 500 ml of a phosphate buffer (pH 7.2), the same agitating procedure was repeated, and 10 ml samples were taken from the test solution (2) at hour 1 and 3 after the start of the agitation, respectively. The sample taken from the test solution (1) was mixed with 2.0 ml of an internal standard (propyl parahydroxybenzoate dissolved in a mixture of water:acetonitrile=7:3), while each of the samples taken from the test solution (2) was mixed with a mixture of 0.5 N HC1 and 2.0 ml of the internal standard. The resulting mixture was filtered through a 0.5 \im membrane filter, and subjected to liquid chromatography (column: Cosmosil (ODS) (4.6x150 mm, 5um) C>g; temperature: 40°C; mobile phase: aqueous HC1O4 (adjusted to pH 2.0 using NaOH);acetonitrile=7:3; flow rate: 1.0 ml/min; injection volume: 500 ul; and wave length: 225 nm) to analyze the time-dependent released amount of tarnsulosin hydrochloride. The results are shown in FIG. 1. As shown in FIG. 1, the capsule of the present invention and Harnal capsule exhibited similar tamsulosin hydrochloride release patterns regardless of the pH. Test Example 2: Stability Test 12 of the hard capsules obtained in Example 17 and 12 of Harnal capsule (Jeil Pharm.) were each placed into a HDPE bottle. Then, the bottle was sealed, and kept at 60°C, or at 40°C and 75% relative humidity (a stress condition). At days 0, 10 or 30 of in such treatment, each residual percentage of tamsulosin hydrochloride in the inventive or Harnal capsule was analyzed using a liquid chromatography, and the results is listed in Table I. Further, using the inventive and Hamal capsules kepted for 10 days under the above stress condition, the procedure of Test Example 1 was repeated. The results are shown in FIGs. 2A (the inventive capsule) and 2B (Hamal capsule). As the results show, the inventive capsule of tamsulosin hydrochloride exhibited high stability and good sustained release charateristics of tamsulosin hydrochloride, comparable to Harnal capsule. Test Example 3: Sphericity Test 10-granule particles of the coated granule obtained in Example 15 and &ose of Harnal capsule were each examined using a microscope (Nikkon SMZ8QO). On each microscopic photograph, a least circumscribed circle of the granule was drawn, and the distance from the circumcenter and surface of the granule was measured to obtam the minimum distance (A) and maximum distance (B). The sphericity of each granule was evaluated by A/B, and the results are listed in Table n. The results in Table n suggest that the granule of the present invention is more spherical than the granule of Harnal, for the average A/B of the inventive granule was closer to 1 than the comparative granule. Thus, composition of the present invention is capable of forming uniform granules. As can be seen from the above, the inventive composition for oral administration of tamsulosin hydrochloride having high stability, a good sustained release rate of the active ingredient and the capability for forming uniform granules can be advantageously used in various fields including medical science and pharmaceutical chemistry. While the invention has been described with respect to the specific embodiments, it should be recognized that various modifications and changes may be made by those skilled in the art to the invention which also fall within the scope of the invention as defined by the appended claims. We claim: 1. A composition for oral administration of tamsulosin hydrochloride comprising tamsulosin hydrochloride, polyvinylacetate, and a water-soluble hydroxypropylmethylcellulose, wherein the amount of polyvinylacetate ranges from 20 to 1000 parts by weight based on 1 part by weight of tamsulosin hydrochloride; wherein the amount of water-soluble hydroxypropylmethylcellulose ranges from 0.1 to 500 parts by weight based on 1 part by weight of tamsulosin hydrochloride. 2. The composition as claimed in claim 1, wherein polyvinylacetate is in the form of a powder or suspension. 3. The composition as claimed in claim 1, wherein the water-soluble hydroxypropylmethylcellulose has a viscosity ranging from 10,000 to 100,000 cps. 4. The composition as claimed in claim 1, wherein the composition is in the form of granule.

Documents:

5205-delnp-2006-1-Correspondence Others-(25-04-2012).pdf

5205-delnp-2006-1-Drawings-(25-04-2012).pdf

5205-DELNP-2006-Abstract-(06-09-2011).pdf

5205-DELNP-2006-Abstract-(25-04-2012).pdf

5205-delnp-2006-abstract.pdf

5205-delnp-2006-assignments.pdf

5205-DELNP-2006-Claims-(06-09-2011).pdf

5205-DELNP-2006-Claims-(25-04-2012).pdf

5205-delnp-2006-claims.pdf

5205-DELNP-2006-Correspondence Others-(06-09-2011).pdf

5205-DELNP-2006-Correspondence Others-(10-06-2011).pdf

5205-DELNP-2006-Correspondence Others-(25-04-2012)..pdf

5205-delnp-2006-correspondence-others-1.pdf

5205-delnp-2006-correspondence-others.pdf

5205-delnp-2006-description (complete).pdf

5205-delnp-2006-drawings.pdf

5205-DELNP-2006-Form-1-(06-09-2011).pdf

5205-delnp-2006-form-1.pdf

5205-delnp-2006-form-18.pdf

5205-DELNP-2006-Form-2-(06-09-2011).pdf

5205-delnp-2006-form-2.pdf

5205-DELNP-2006-Form-3-(10-06-2011).pdf

5205-delnp-2006-form-3.pdf

5205-delnp-2006-form-6.pdf

5205-DELNP-2006-GPA-(06-09-2011).pdf

5205-DELNP-2006-GPA-(25-04-2012).pdf

5205-delnp-2006-pct-101.pdf

5205-delnp-2006-pct-210.pdf

5205-delnp-2006-pct-237.pdf

5205-delnp-2006-pct-304.pdf

5205-delnp-2006-pct-308.pdf

5205-delnp-2006-pct-409.pdf